$COGT
Cogent Biosciences, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022019089 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.948M $4.590M
YoY Change 29.59% 25.07%
% of Gross Profit
Research & Development $25.47M $8.210M
YoY Change 210.23% -13.56%
% of Gross Profit
Depreciation & Amortization $69.00K $20.00K
YoY Change 245.0% -93.33%
% of Gross Profit
Operating Expenses $31.42M $12.80M
YoY Change 145.45% 34.77%
Operating Profit -$31.42M
YoY Change
Interest Expense $107.0K $130.0K
YoY Change -17.69% 160.0%
% of Operating Profit
Other Income/Expense, Net $677.0K $1.072M
YoY Change -36.85% 2180.85%
Pretax Income -$30.63M -$11.73M
YoY Change 161.16% 92.61%
Income Tax
% Of Pretax Income
Net Earnings -$30.63M -$11.73M
YoY Change 161.2% 92.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.68
Diluted Earnings Per Share -$679.2K -$336.3K
COMMON SHARES
Basic Shares Outstanding 45.11M
Diluted Shares Outstanding 45.11M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $191.0M $230.7M
YoY Change -17.19% 679.39%
Cash & Equivalents $192.3M $232.0M
Short-Term Investments
Other Short-Term Assets $3.686M $1.300M
YoY Change 183.54% -18.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $194.7M $232.1M
YoY Change -16.1% 644.27%
LONG-TERM ASSETS
Property, Plant & Equipment $5.275M $4.300M
YoY Change 22.67% 173.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.861M $1.300M
YoY Change 427.77% 0.0%
Total Long-Term Assets $12.14M $5.510M
YoY Change 120.25% -28.94%
TOTAL ASSETS
Total Short-Term Assets $194.7M $232.1M
Total Long-Term Assets $12.14M $5.510M
Total Assets $206.9M $237.6M
YoY Change -12.94% 510.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.015M $315.0K
YoY Change 1174.6% -49.84%
Accrued Expenses $10.55M $3.800M
YoY Change 177.68% -44.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.88M $8.242M
YoY Change 116.93% -10.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.127M $2.600M
YoY Change -56.65% -35.0%
Total Long-Term Liabilities $1.127M $2.600M
YoY Change -56.65% -35.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.88M $8.242M
Total Long-Term Liabilities $1.127M $2.600M
Total Liabilities $19.01M $10.85M
YoY Change 75.22% -18.06%
SHAREHOLDERS EQUITY
Retained Earnings -$301.6M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $187.9M $226.8M
YoY Change
Total Liabilities & Shareholders Equity $206.9M $237.6M
YoY Change -12.93% 510.19%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$30.63M -$11.73M
YoY Change 161.2% 92.45%
Depreciation, Depletion And Amortization $69.00K $20.00K
YoY Change 245.0% -93.33%
Cash From Operating Activities -$28.33M -$11.37M
YoY Change 149.29% 44.0%
INVESTING ACTIVITIES
Capital Expenditures $441.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$441.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 138.0K -85.00K
YoY Change -262.35% -216.44%
NET CHANGE
Cash From Operating Activities -28.33M -11.37M
Cash From Investing Activities -441.0K
Cash From Financing Activities 138.0K -85.00K
Net Change In Cash -28.64M -11.45M
YoY Change 150.08% 46.43%
FREE CASH FLOW
Cash From Operating Activities -$28.33M -$11.37M
Capital Expenditures $441.0K
Free Cash Flow -$28.78M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43805922
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43805922
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
399713000
CY2021Q1 cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-446000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1879000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
532000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-417000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
199000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2029000
CY2022Q1 cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-550000
CY2021Q1 cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-485000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28334000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11366000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
441000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-441000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
129000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000
CY2021Q1 cogt Payment To Contingent Value Right Holders
PaymentToContingentValueRightHolders
85000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
138000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-85000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28637000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11451000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220939000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
243445000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192302000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231994000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
917000
CY2022Q1 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
7000000
CY2021Q1 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
16200000
CY2021Q1 us-gaap Stock Issued1
StockIssued1
2043000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-30600000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301600000
CY2021Q4 cogt Contingent Value Right Liability Current
ContingentValueRightLiabilityCurrent
3060000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2324000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9000000
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
677000
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
604000
CY2021Q1 cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-343000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-30634000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
214184000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
129000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4175000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-30634000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
187863000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
234667000
CY2021Q1 cogt Issuance Of Common Stock Value To Settle Liability
IssuanceOfCommonStockValueToSettleLiability
2043000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
260000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11728000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
226763000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-11728000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4175000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1781000
CY2021Q1 cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-343000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
737000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1392000
CY2022Q1 cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-491000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#222222;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#222222;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of the CVR liability and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</p>
CY2020Q3 us-gaap Share Price
SharePrice
8.80
CY2022Q1 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2021Q1 cogt Fair Value Assets Transfers Between Level One Two And Three
FairValueAssetsTransfersBetweenLevelOneTwoAndThree
0
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1454000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3389000
CY2022Q1 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4181000
CY2021Q1 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1953000
CY2022Q1 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
427000
CY2021Q1 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
1556000
CY2022Q1 cogt Accrued Professional And Consulting Services
AccruedProfessionalAndConsultingServices
2095000
CY2021Q1 cogt Accrued Professional And Consulting Services
AccruedProfessionalAndConsultingServices
1077000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
235000
CY2022Q1 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
8409000
CY2021Q1 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
8210000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 cogt Preferred Stock Including Temporary Equity Shares Authorized
PreferredStockIncludingTemporaryEquitySharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4175000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1781000
CY2022Q1 cogt Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2023-04
CY2022Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
the Company’s option to extend for an additional five-year term.
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
900000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
900000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
612000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
261000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
652000
CY2022Q1 us-gaap Lease Cost
LeaseCost
221000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
873000
CY2022Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0893
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1885000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
928000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
134000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
138000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
141000
CY2022Q1 cogt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1370000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4596000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
886000
CY2022Q1 cogt Lessee Operating Lease Liability Tenant Improvement Allowance Receivable
LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable
188000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3522000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2395000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1127000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3522000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-30634000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11728000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30634000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11728000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45105923
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34879296
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35934896
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32613111
CY2022Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000

Files In Submission

Name View Source Status
0001564590-22-019089-index-headers.html Edgar Link pending
0001564590-22-019089-index.html Edgar Link pending
0001564590-22-019089.txt Edgar Link pending
0001564590-22-019089-xbrl.zip Edgar Link pending
cogt-10q_20220331.htm Edgar Link pending
cogt-10q_20220331_htm.xml Edgar Link completed
cogt-20220331.xsd Edgar Link pending
cogt-20220331_cal.xml Edgar Link unprocessable
cogt-20220331_def.xml Edgar Link unprocessable
cogt-20220331_lab.xml Edgar Link unprocessable
cogt-20220331_pre.xml Edgar Link unprocessable
cogt-ex101_49.htm Edgar Link pending
cogt-ex311_6.htm Edgar Link pending
cogt-ex312_8.htm Edgar Link pending
cogt-ex321_9.htm Edgar Link pending
cogt-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gdr4hybz3mg3000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending